MYO · Myomo, Inc.
$0.93
-0.02 (-2.61%)
At close · Jul 29
Market Cap
$36.90M
Shares
38.64M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.93
Open$0.98
Day$0.91–0.98
52W$0.61–2.06
Avg vol 30d713K
Short int2.4M · 6.2% float · 6.9d
Short vol37%
Last earningsMay 7, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 7
Up next
Next earnings call
Aug 9, 2026
Est · unconfirmed
· in 1 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 20.7 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+0%
above
Price vs 50-day avg
−16%
below
RSI (14)
42
neutral
MACD trend
Negative
52-week position
22%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−11%
trailing
6-month return
+15%
trailing
YTD return
+2%
this year
Relative strength
+9%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Distributing
17 of 81 funds reported for Jun 30 · net -36.4K sh shares · +1 new
Insider flow
Accumulating
Net +$207.8K over 90 days · 50% sells
Short interest
Falling
6.24% of float · ▼ -1.2% MoM · 6.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
81 holders — near 3-yr high, broad support
Squeeze score
57
elevated · 0–100
Fundamentals
Revenue growth
+40815%
Y/Y
Gross margin
3%
contracting
EPS growth
−131%
Y/Y
Free cash flow
$-16.3M
Balance sheet
$10.3M
net cash
Quant / Vol
risk profile
Volatility
98%
annualized · 1-yr
Max drawdown
−68%
past year
ATR
11.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 7, 2026
second quarter 2026
Revenue
Initiated
$10.3M – $10.8M
prior qtr $10.11M
midpoint +4.3% QoQ
full year
Revenue
Initiated
$43M – $46M
prior FY $40.93M
midpoint +8.7% Y/Y
Guided vs delivered
· last 1 settled
Revenue
full 2025 annual
guided $40M – $42M
$40.93M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+0%
Bullish
Price vs 50-day avg
−16%
Bearish
RSI (14)
42
Neutral
MACD trend
Negative
Bearish
52-week position
22%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Distributing
17 of 81 funds reported for Jun 30 · net -36.4K sh shares · +1 new
Insider flow
Accumulating
Net +$207.8K over 90 days · 50% sells
Short interest
Falling
6.24% of float · ▼ -1.2% MoM · 6.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
81 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $1 · 22%
52-wk high $2
vs 200-day avg +0%
vs 50-day avg -16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$2.3M | Q1 2026 | — |
|
|
|||
| Average selling price (ASP) | $58,800 | Q1 2026 | — |
|
|
|||
| Backlog | 226 | as of March 31, 2026 | — |
| cost per pipeline add | $2,550 | Q1 2026 | — |
|
|
|||
| MyoPro orders | 239 | Q1 2026 | — |
|
|
|||
| MyoPro revenue units | 172 | Q1 2026 | — |
|
|
|||
| patients added to the pipeline | 723 | Q1 2026 | — |
|
|
|||
| Recurring patient sources as % of revenue | 49% | Q1 2026 | — |
|
|
|||
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MYO
this stock
Myomo, Inc.
|
$36.90M | +2.2% | +41.3% | — | 6.2% |
|
ABT
Abbott Laboratories
|
$188.12B | -13.4% | +5.7% | 30.3 | 1.4% |
|
SYK
Stryker Corp
|
$132.87B | +0.5% | +11.2% | 40.1 | 1.8% |
|
MDT
Medtronic plc
|
$111.21B | -8.1% | +8.4% | 23.3 | 1.5% |
|
BSX
Boston Scientific Corp
|
$68.43B | -51.7% | +5.5% | 19.3 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MYO | -10.6% | -10.6% | +14.8% | -10.6% | +2.2% |
| SPY | -2.4% | -2.3% | +6.3% | -2.3% | +7.0% |
| vs SPY | -8.2% | -8.3% | +8.5% | -8.3% | -4.8% |
Key facts
CIK
1369290
CUSIP
62857J201
13F (30d)
13 filings
13 filers
Visit website
Investor relations